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A more flexible and higher-yielding in vitro DNA mismatch repair (MMR) substrate construction 
method, which was developed initially by Wang and Hays, is described for the construction of 
a nucleotide-based chemical mismatch (G/IU) and a G/T mismatch. Our modifications use the 
combination of two endonuclease enzymes (NheI and BciVI) and two new redesigned plasmids 
(pWDAH1A and pWDSH1B). In our modified methodology, plasmids are initially digested with 
the nicking endonucleases, followed by the streptavidin treatment. The mismatch-containing 
oligo is then annealed to the gap DNA and finally ligated to produce a mismatch-containing 
DNA substrate. We report a high efficiency (up to 90%) of these mismatch substrates and 
confirm recognition using a functional assay. These modifications, coupled with the use of the 
redesigned plasmids, can be applied for the construction of other types of chemically induced 
mismatches as well as insertion-deletion loops for future in vitro studies of MMR processing 
by our group and others.
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in excessive cytotoxicity per se, but does enhance cell killing with 
subsequent exposure to ionizing radiation. As such, the use of IUdR 
or its prodrug IPdR, during radiation therapy has been used in 
pre-clinical studies to “target” MMR-deficient cancers while spar-
ing normal (MMR-proficient) tissues (Berry and Kinsella, 2001; 
Berry et al., 2003; Seo et al., 2004). Other types of nucleoside ana-
logs, such as the fluoropyrimidine, 5-fluorouracil (5-FU) and the 
purine analog, 6-thioguanine (6-TG), which are used clinically as 
cancer chemotherapeutic agents, are also processed by MMR but 
result in marked cytotoxicity in MMR-proficient cells compared 
to IUdR whereas MMR-deficient tumor cells show clear damage-
tolerance in pre-clinical and clinical studies to 5-FU and 6-TG 
(Berry and Kinsella, 2001; Meyers et al., 2001; Berry et al., 2003; 
Li, 2008; Kinsella, 2009).
To begin to better understand the observed cellular differences 
in MMR processing of specific DNA mismatches resulting from 
treatment with different nucleoside analogs (IUdR, 5-FU, 6-TG) 
compared to endogenous mismatches like G/T, we initially plan to 
use using a purified protein system as described by the Modrich 
and Li laboratories (Zhang et al., 2005; Modrich, 2006; York and 
Modrich, 2006). However, as opposed to the construction of a G/T 
mismatch, these nucleotide based mismatches such as G/IU require 
the use of synthetic oligomers, as IUdR cannot be produced in cells 
or by a PCR methodology. As part of our preliminary investigations 
into MMR processing of specific nucleoside based mismatches, we 
developed several more efficient modifications to the method of 
Wang and Hays (2006) for the construction of a G/IU incorporated 
plasmid substrate. Our modifications include the use of a different 
combination of endonuclease enzymes, NheI/BciVI, and two new 
redesigned plasmids, pWDAH1A and pWDSH1B, in the construc-
tion of supercoiled G/IU versus G/T mismatch-containing DNA. 
Together, the advancements to the in vitro MMR assay described 
IntroductIon
DNA mismatches may arise from endogenous replication errors or 
from exogenous sources including occupational and therapeutic 
chemical and ionizing radiation exposures. These mismatches may 
be repaired during scheduled or unscheduled DNA synthesis by the 
DNA mismatch repair (MMR) pathway (for reviews, see references 
Kunkel and Erie, 2005; Iyer et al., 2006; Modrich, 2006; Li, 2008), 
as well as by other DNA repair pathways such as base excision 
repair (BER; Kinsella, 2009). Failure to correct these mismatches by 
MMR may significantly increase the incidence of cancer in patients 
with genetic defects (e.g., hereditary non-polyposis colon cancer; 
Bellizzi and Frankel, 2009). Additionally, epigenetic silencing by 
promoter methylation of MMR genes (particularly MLH1 and 
MSH2) is associated with sporadic cancers of gastrointestinal, 
gynecological and genitourinary origin, which are characterized 
by a microsatellite instability-high (MSI-H) phenotype (Bellizzi 
and Frankel, 2009). MMR-deficient cancers are reported to be 
resistant, or more accurately, damage-tolerant, to cytotoxicity by 
various classes of chemotherapeutic agents including nucleoside 
analogs and to certain types of ionizing radiation (Li, 2008; Kinsella, 
2009; Yan et al., 2009). Consequently, a better understanding of how 
MMR processes non-classical DNA mismatches may be helpful in 
designing cancer prevention strategies as well as in developing novel 
cancer therapeutics for MMR-deficient cancers.
Our laboratory initially reported that incorporation of the 
halogenated thymidine analog, iododeoxyuridine (IUdR) causes 
specific DNA mismatches, particularly G/IU, which are efficiently 
processed by MMR (Berry and Kinsella, 2001; Berry et al., 2003). 
In fact, MMR-deficient cancer cells and human tumor xenografts 
retain higher levels of IUdR–DNA incorporation compared to 
MMR-proficient cells. However, the increased percentage IUdR–
DNA incorporation in MMR-deficient cells/tumors does not result Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 8  |  2
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into nick DNA. Agarose gel electrophoresis was used to confirm 
the digestion. Digestion was stopped by denaturation at 90°C for 
10 min, followed by gradually cooling down to room temperature, 
in the presence of 20-fold excess of a biotinylated 43-mer oligo 
(Biotin-GATCGACTCTGATCAAGCTTAAGGATGCTAGCAGGT 
GTCGACG), which is complementary to the fragment between 
the two nicks. The 43-nt fragment released under the denaturat-
ing conditions was annealed to the excess biotinylated oligos to 
form dsDNA to facilitate removal. These biotinylated oligos (either 
single-stranded or double-stranded) were removed by centrifuga-
tion using a Amicon Ultra-4 50K column (Millipore, Billerica, MA, 
USA). Most of the excess oligos were removed by initial centrifuga-
tion and the remaining trace oligos were removed by subsequent 
passage through a streptavidin column. The passage through the 
column also concentrated the crude gap DNA. DNA concentra-
tions were monitored using a NanoDrop 1000 spectrophotometer 
(NanoDrop, Wilmington, DE, USA) and were confirmed by agarose 
gel electrophoresis. The removal of the 43-nt fragment inhibited 
recognition reaction of NheI, as the anti-sense strand is now single-
stranded. Our calculation based on the comparison before and after 
filtration indicated that 90% of gap DNA is recovered.
However, contamination of the remaining 10% of impurity in 
the gap DNA is too much and unacceptable. Consequently, any 
residual impurity DNA (mostly nicked DNA) is initially ligated, 
in the presence of NEBuffer 4 buffer, ligase and ATP, into super-
coiled DNA. The supercoiled DNA is then separated using CsCl 
density-gradient ultracentrifugation and the target band is recov-
ered using SSC (Saline Sodium Citrate) saturated isopropanol to 
extract Ethidium Bromide. Briefly, for 1 ml the ligated products, 
1 g of CsCl is added to an Ultra-clear tube (Beckman, Palo Alto, 
CA, USA) and a SW50.1 rotor (Beckman) is used in the Beckman 
L7 ultracentrifuge for 48 h at a speed of 50000 rpm. The band is 
identified under UV light and recovered.
LIgatIon of nIcked dsdna wIth mIsmatch(s)
5′-end phosphorylated 43-nt oligos are added to the gap DNA at 
1:1 ratio to produce a mismatched or matched DNA. The anneal-
ing reaction is performed in the presence of NEBuffer 4 buffer 
at 90°C for 30 s and then cooled at a rate of 0.1°C/s using a MJ 
Research Thermal Cycler (now Bio-Rad, Hercules, CA, USA). Then, 
1 mM of ATP and 100 units of T4 DNA ligase in 500 μl reaction 
volume are used for the ligation reaction and kept overnight at 
room temperature.
Under this condition, we found a ligation efficiency of up to 
90%, as judged by agarose gel electrophoresis, significantly higher 
than the prior method, which reported an efficiency of 50% (Wang 
and Hays, 2006). The ligation products are then digested by NheI 
to check whether it could cleave the mismatch-containing DNA 
recognition sites. This ligation reaction produced a mixture of cir-
cular dsDNA without nick (ligated) and circular dsDNA with nick 
(un-ligated). To further purify the mismatched DNA, CsCl density-
gradient ultracentrifugation was applied again, as described above.
IdentIfIcatIon and confIrmatIon of mIsmatched dna
Both strands of the constructed mismatch DNA are sequenced to 
confirm the presence of the mismatch. Note that in this case, the 
mismatched nucleotides in the template will pair with a cytosine in 
here provide an opportunity to more rapidly and efficiently inves-




The original plasmids pSYAH1A and pSYSH1B were kindly 
provided by York and Modrich (2006; Duke University). These 
pUC19Y-derived plasmids (originally from Dr. Hays’ lab) were used 
to construct both pSYAH1A and pSYSH1B, the only difference of 
which is they share the same insertion fragment, but are inserted 
into the parental plasmid in opposite directions. All enzymes, 
including Nt.BbvCI, Nt.BstNBI, and T4 DNA ligase, were obtained 
from New England Biolab (NEB, Boston, MA, USA), except where 
otherwise noted. Oligonucleotides (oligos) and biotinylated oligos 
were synthesized by Invitrogen (Carlsbad, CA, USA), while the 
IUdR-containing oligo was from Operon (Huntsville, AL, USA). 
Streptavidin beads were purchased from Invitrogen and the strepta-
vidin column was from GE Healthcare (Piscataway, NJ, USA).
PreParatIon of PLasmId dna
To construct DNA substrates, we redesigned the insertion 
sequence of the plasmid pSYAH1A so that the newly designed 
plasmids have overlapping restrictive sites of NheI and a latent 
BciVI site. The source plasmid pSYAH1A was digested using SalI 
and AatII, and the purified linear double-stranded (ds)DNA was 
annealed to the following sequences: 5′-CGAGTCGATCCGT 
CGACACCTGCTAGCATCCTTAAGCTTGATCAGAGTCGATC 
CG-3′ and 5′-TCGACGG ATCGACTCTGATCAAGCTTAAGG 
ATCTAGCAGGTGTC GAC GGAT CGACTCGACGT-3′. This 
new plasmid is named pWDAH1A, which has two Nt.BstNBI 
recognition sites in the sense strand, parting from a fragment 
of 43 nucleotides. The mismatch of either “T” or “IU” will be 
introduced by replacing this fragment with a synthetic segment. 
For the pWDSH1B plasmid, we used the following sequences 
as insertions: 5′-TCGACGAGTCGATCCGAGCTCACCTGC 
TAGCATCCTTAAGCTTGATCAGAGTCGATCCGACGT-3′ and 
5′-CGGATCGACTCTGA TCAAGCTTAAG GATGCTAGCAGGTG 
AGCTCGGATCGACTCG-3′. The two plasmids share the same but 
inverted sequence.
The annealed oligos and SalI/AatII digested linearized DNA were 
ligated by T4 DNA ligase at room temperature and then grown 
in bacterial supercompetent XL10 cells (Stratagene, La Jolla, CA, 
USA) for 16 h following the manufacturer’s manual. The plasmids 
were extracted using a Marligen Miniprep kit (Marligen, Rockville, 
MD, USA). Purified plasmids were fully sequenced and confirmed 
in both strands.
For large-scale preparation, pWDAH1A plasmid-containing 
bacteria XL10 cells were grown in approximately 1000 ml of LB 
broth (USB, Cleveland, OH, USA). High purity and high quality 
plasmids were harvested according to the manufacturer’s manual.
generatIon of gaP dna
For a typical digestion reaction, 400 μg of plasmid DNA were used 
and 400 units of Nt.BstNBI were added in the reaction contain-
ing NEBuffer 3 buffer, and digestion was performed at 55°C for 
4–6 h. At least 90% of supercoiled plasmid DNA was transformed www.frontiersin.org  June 2011  | Volume 1  |  Article 8  |  3
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To construct a heteroduplex with a G/IU mismatch, we rede-
signed two plasmids (pWDAH1A and pWDSH1B plasmid) for 
subsequent DNA mismatch substrate construction (Figure 1). The 
pWDAH1A plasmid has two Nt.BstNBI sites both in the anti-sense 
strand, whereas pWDSH1B has two identical inverted nick sites in 
the sense strand. Both plasmids have NheI and a latent overlapping 
BciVI recognition site (Figure 1). These plasmids are sequenced and 
confirmed in both directions. Our preliminary data indicate that 
NheI cannot recognize and cleave the newly designed G/T and G/
IU combination (data not shown), which means this combination 
is applicable to our experiment.
The overall approach is illustrated in Figure 2. Briefly, Nt.BstNBI 
digestion is first used to produce a dual-nick DNA; the products 
are then centrifuged and bound to a streptavidin column to obtain 
gap DNA. The mismatch-introducing oligo is annealed with the 
gap DNA followed by ligation to yield the mismatch-containing 
heteroduplex DNA. Following CsCl gradient ultracentrifugation, 
the DNA substrates are nicked with the nicking nucleases.
ProductIon of gaP dna
To generate the gap DNA, we used a simple strategy to remove the 
short 43-nt oligo between two Nt.BstNBI recognition sites (Figure 2, 
steps 2 and 3). A slow cool-down following heat denaturation facili-
tates the pairing of a biotinylated complementary oligo with the 
oligo released to form dsDNA. Centrifugation using Amicon cen-
trifugal filter units (MW cut-off 50K) from Millipore removed most 
of the oligos (Figure 3, lane 4), while the remaining small amount of 
the oligo can be removed by passage through a streptavidin column 
to acquire as high efficiency as possible(Figure 3, lane 5).
However, gap DNA remains only 90% pure, as there is small 
amount of single-nick DNA or undigested DNA in mixture (esti-
mation from lanes 7 and 8 of Figure 3 indicates that approximately 
10% is impurity). To assess the purity of gap DNA, the ligation 
reaction and NheI-digested reaction are performed. As shown in 
Figure 3, lanes 7 and 8, compared with the original undigested 
the daughter strand. The purified ligated DNA construct with the mis-
match is then digested using Nt.BbvCI (to produce a nick in the anti-
sense strand approximately 200-nt 5′ to the mismatch) or Nb.BbvCI 
(to produce a nick in the sense strand, 200-nt 3′ to the mismatch).
Nuclear extract and DNA substrate are incubated to assess mis-
match correction. The nuclear extract is obtained from Active Motif 
(Carlsbad, CA, USA). The DNA substrate is mixed with nuclear 
extract in the presence of the following buffer solution: 20 mM 
Tris/HCl (pH 7.6), 1.5 mM ATP, 1 mM glutathione, 100 μM dNTP, 
5 mM MgCl2, and 50 μg/ml BSA. After incubation at 37°C for 
20 min, proteinase K buffer (10 mM Tris/HCl, 5 mM EDTA, 0.5% 
SDS) is added and the incubation is continued for 60 min at 37°C. 
DNA is precipitated by sequential phenol and ethanol exposures. 
The DNA is next dissolved in nuclease-free water and subjected 
to digestion using NheI. Since NheI cannot cleave a G/T or G/IU 
mismatch, any additional band that appeared indicated that the 
DNA substrate has been repaired by the nuclear extract.
resuLts and dIscussIon
two newLy desIgned PLasmIds
The thymidine analog IUdR, an effective radiosensitizer, is known 
to be incorporated into genomic DNA after administration and 
can activate MMR processing. Our specific interest is not only to 
understand how MMR works, but also to learn how MMR processes 
exogenous chemically induced analogs (York and Modrich, 2006), 
compared to endogenous mismatches. The most widely used strategy 
to study endogenous MMR is to use a T/G mismatch and a combi-
nation of HindIII/XhoI recognition sites (Fang and Modrich, 1993; 
Wang and Hays, 2000, 2001; Constantin et al., 2005; Zhang et al., 
2005) in a purified protein system (Constantin et al., 2005; Zhang 
et al., 2005) or with nuclear extracts (Wang and Hays, 2001, 2006). 
However, the T/G and HindIII/XhoI combination is not suitable to 
study MMR processing of our G/IU mismatch, as the presence of 
unnatural IUdR makes the repaired nucleotide un-identifiable by 
XhoI. We thus sought to develop a new restriction combination.
Figure 1 | Sequences of the newly designed plasmid, containing a Nhei site and a latent BciVi recognition site. The 43-nt fragment between two Nt.BstNBI 
sites in the anti-sense strand can be replaced by a new mismatch-containing oligo to produce a mismatch substrate.Frontiers in Oncology | Radiation Oncology    June 2011  | Volume 1  |  Article 8  |  4
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generatIon of the mIsmatched nIck dna
The mismatch (T/G or IU/G) containing oligo is annealed with 
gap DNA, the oligo is inserted into the gap and ligated in the pres-
ence of 1 mM ATP. Our agarose gel electrophoresis indicated that 
the ligation efficiency is high (up to 90%), as shown in Figure 4, 
lane 4 (G/T mismatch) and lane 5(G/IU), where the nicked DNA 
binds with more Ethidium Bromide dye when compared with the 
supercoiled DNA. The ligated circular closed DNA is subjected to 
CsCl density-gradient centrifugation again.
The recovered DNA is then sequenced for confirmation of 
the mismatch. As shown in Figure 5, sequencing data confirmed 
the presence of a G/T mismatch. Note that the nucleotides of the 
original G/T mismatch will be exhibited as A/C in the sequenc-
ing reaction. For G/IU mismatch, there is a difference. When the 
template (sense strand) is “G,” the newly polymerized strand in the 
sequencing reaction is shown as a “C” as expected; however, when 
the template in the anti-sense strand contains IU, DNA polymerase 
would select a “G” in the G/T mismatch, to match the non-naturally 
occurring IU. Hence, it will show a “G/C.” However, these results 
do not suggest that this is a paired match DNA, as our digestion 
analysis indicates that NheI is unable to cleave the DNA, implying 
the presence of the mismatch (Figure 4, lane 8). To our knowledge, 
it is the first available sequencing data containing IUdR in the tem-
plate strand and the first report that DNA polymerase will select 
“C” as a complementary nucleotide.
The closed circular DNA is digested by either Nt.BbvCI (in 
the anti-sense strand) or Nb.BbvCI (in the sense strand) to intro-
duce a nick which mimics the template strand. The two plasmids 
make construction of four DNA substrates are available for 
MMR analysis.
confIrmatIon of mIsmatch dna substrate
To further confirm that the new construct serves as a DNA sub-
strate in the MMR study, we performed a functional assay using 
the MMR-proficient HeLa S3 nuclear extract (product of Active 
Motif). As shown in Figure 6, the nuclear extract data demonstrate 
that a mismatch DNA substrate is recognized and repaired such that 
the mismatched “T” or “IU” in the daughter strand is removed and 
replaced by a “C,” which restores the NheI recognition site, clearly 
indicating the success of our substrate constructions.
Figure 2 | illustration of the whole procedure of this new method. (1) the 
original pWDAH1A/SH1B plasmid; (2) Nt.BstNBI digestion to produce two 
nicks followed by addition of 20× biotinylated supplementary oligo; (3) two 
rounds of treatment with streptavidin beads and column to remove the 
biotinylated oligo to generate gap DNA; (4) the mismatch-containing DNA 
oligo added to anneal with the gap DNA, followed by a ligation reaction; (5) 
CsCl density ultracentrifuge, DNA recovery, and nick generation using 
Nt.BbvCI or Nb.BbvCI; (6) mismatch-containing DNA substrate (G/T mismatch 
or G/IU).
Figure 3 | identification of gap DNA. Lane 1: 200 ng of pWDAH1A 
plasmid; Lane 2: Nt.BstNBI-digested pWDAH1A plasmid (Nick DNA), 200 ng; 
Lane 3: Nt.BstNBI-digested pWDAH1A plasmid + biotinylated Rem-seq oligo; 
Lane 4: flow-through of mixture of lane 3; Lane 5: gap DNA, 200 ng; Lane 6: 
NheI-digested pWDAH1A plasmid DNA (linear DNA); Lane 7: NheI digestion 
of 200 ng gap DNA; Lane 8: ligation of gap DNA. Two hundred nanograms of 
DNA loaded each lane.
DNA (lane 1), most of original plasmid has been transformed 
into gap DNA, while NheI digestion of DNA found some impu-
rity. Those approximately 10% of impurities should represent 
incompletely digested plasmid. The less pure gap DNA is then 
ligated. The formation of the nicked DNA by the ligation reac-
tion into supercoiling DNA makes it easier to separate from gap 
DNA by our CsCl density-gradient ultracentrifugation method 
described above.
Figure 4 | generation and identification of the mismatch DNA 
substrate. Lane 1: pWDAH1A plasmid (supercoiled DNA); Lane 2, 3: gap DNA 
obtained after CsCl gradient ultracentrifuge + oligo (containing “T” or “IUdR”) 
heteroduplex, without ligation; Lane 4, 5: ligation of lane 2 and 3, gap 
DNA + mismatch-introducing oligo to produce G/T mismatch; Lane 6: NheI 
digestion of pWDAH1A plasmid; Lane 7 , 8: NheI digestion of G/T- or G/
IU-containing DNA; Lane 9: CsCl-method recovered mismatch DNA (G/T); 
Lane 10, 11: Nt.BbvCI-digested nick G/T or G/IU mismatch DNA as a DNA 
substrate.www.frontiersin.org  June 2011  | Volume 1  |  Article 8  |  5
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